GPR174: A GPCR Targeted for Pain and Neurodegenerative Diseases
GPR174: A GPCR Targeted for Pain and Neurodegenerative Diseases
GPR174 (LYPSR3) is a G protein-coupled receptor (GPCR) that is expressed in various tissues and cells in the body. It is a member of the LYPR family of GPCRs, which are a subclass of GPCRs that are characterized by the presence of a leucine-rich repeat (LRR) in the extracellular domain. GPR174 is a potential drug target (or biomarker) due to its unique structure and the involvement of several research groups in the study of its function.
GPR174 is a GPCR that is expressed in the brain, heart, skeletal muscles, and other tissues. It is primarily localized to the plasma membrane of cells and is involved in several signaling pathways. GPR174 is a potent modulator of pain perception and neuropeptide signaling, which suggests that it may have a role in the treatment of pain disorders.
One of the unique features of GPR174 is its LRR, which is a 21-amino acid residue that is rich in leucine. The LRR is involved in the formation of a disulfide bond, which is characteristic of GPCRs. This feature allows GPR174 to interact with other GPCRs and G protein-coupled receptors, which is important for its function.
GPR174 is involved in several signaling pathways, including pain perception, neuropeptide signaling, and cell survival. For example, GPR174 is involved in the regulation of pain sensitivity and in the modulation of neuropeptide release from terminals in the brain. Additionally, GPR174 is involved in the regulation of cell survival and has been shown to play a role in the development and progression of cancer.
GPR174 is also a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and pain disorders. For example, GPR174 has been shown to be involved in the regulation of cancer cell migration and has been used as a potential therapeutic target in cancer treatment. Additionally, GPR174 has been shown to be involved in the regulation of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.
Due to its unique structure and the involvement of several research groups, GPR174 is a promising drug target (or biomarker) with potential for the treatment of pain disorders and other diseases. Further research is needed to fully understand the function of GPR174 and its potential as a drug target.
Protein Name: G Protein-coupled Receptor 174
Functions: Putative receptor for purines coupled to G-proteins
More Common Targets
GPR176 | GPR179 | GPR18 | GPR180 | GPR182 | GPR183 | GPR19 | GPR199P | GPR20 | GPR21 | GPR22 | GPR25 | GPR26 | GPR27 | GPR3 | GPR31 | GPR32 | GPR33 | GPR34 | GPR35 | GPR37 | GPR37L1 | GPR39 | GPR4 | GPR42 | GPR45 | GPR50 | GPR52 | GPR55 | GPR6 | GPR61 | GPR62 | GPR63 | GPR65 | GPR68 | GPR75 | GPR75-ASB3 | GPR78 | GPR79 | GPR82 | GPR83 | GPR84 | GPR84-AS1 | GPR85 | GPR87 | GPR88 | GPR89A | GPR89B | GPRACR | GPRASP1 | GPRASP2 | GPRASP3 | GPRC5A | GPRC5B | GPRC5C | GPRC5D | GPRC5D-AS1 | GPRC6A | GPRIN1 | GPRIN2 | GPRIN3 | GPS, PLAT and transmembrane domain-containing protein | GPS1 | GPS2 | GPS2P1 | GPSM1 | GPSM2 | GPSM3 | GPT | GPT2 | GPX1 | GPX1P1 | GPX2 | GPX3 | GPX4 | GPX5 | GPX6 | GPX7 | GPX8 | GRAMD1A | GRAMD1B | GRAMD1C | GRAMD2A | GRAMD2B | GRAMD4 | GRAMD4P2 | GRAMD4P5 | GRAMD4P7 | Granzyme | GRAP | GRAP2 | GRAPL | GRAPL-AS1 | GRASLND | GRB10 | GRB14 | GRB2 | GRB7 | GREB1 | GREB1L
